Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASLAN004 in moderate-to-severe atopic dermatitis
NCT05158023Phase 2Completed
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of eblasakimab in atopic dermatitis (AD) (5 arms), sponsored by ASLAN Pharmaceuticals. Primary endpoint: Percent change from Baseline in Eczema Area and Severity Index at 16 weeks. Started Mar 2022; status: completed.
02
Drugs
eblasakimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05158023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05158023.